Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Isacson, Ole ^a   Bjorklund, Lars M ^a   Schumacher, James M ^b   Kordower, ^c   Olanow, ^c   Brooks, ^c   Rascol, ^c   Stocchi, ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c University of Miami ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; CELL RENEWAL; CLINICAL TRIAL; CYTOLOGY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; HUMAN; NERVE ENDING; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; SYNAPSE;

CORPUS STRIATUM; DOPAMINE; FETAL TISSUE TRANSPLANTATION; HUMANS; MESENCEPHALON; NERVE DEGENERATION; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

EID: 0037378784     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10482     Document Type: Review

References (110)

1. Bjorklund LM, Isacson O. Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res 2002;138:411-440.
2. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
3. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 1999;2:1137-1140.
4. Strecker RE, Sharp T, Brundin P, et al. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987;22:169-178.
5. Zetterstrom T, Ungerstedt U. Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. Eur J Pharmacol 1984;97:29-36.
6. Isacson O, Deacon TW. Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurosci 1997;20:477-482.
7. Bjorklund LM, Sánchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002;99:2344-2349.
8. Isacson O, Deacon TW, Pakzaban P, et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995;1:1189-1194.
9. Isacson O, Deacon TW. Specific axon guidance factors persist in the mature rat brain: evidence from fetal neuronal xenografts. Neuroscience 1996;75:827-837.
10. Haque NS, LeBlanc CJ, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant 1997;6:239-248.
11. Isacson O, Bjorklund L, Pernaute RS. Parkinson's disease: interpretations of transplantation study are erroneous. Nat Neurosci 2001;4:553.
12. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47:167-178.
13. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 2000;22:123-144.
14. Madrazo I, Leon V, Torres C. Transplantation of fetal substantia nigra and adrenal medulla to the caudate putamen in two patients with Parkinson's disease. N Engl J Med 1988;318:51.
15. Backlund E, Granberg, P., Hamberger, B. Transplantation of adrenal medullary tissue to striatum in parkinsonism. J Neurosurg 1985;62:169-173.
16. Widner H, Tetrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. N Engl J Med 1992;327:1556-1563.
17. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995;38:379-388.
18. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 and 46 months after transplantation for Parkinson's disease. N Engl J Med 1992;327:1549-1555.
19. Kordower JH, Rosenstein JM, Collier TJ, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, ultrastructural, and metabolic studies. J Comp Neurol 1996;370:203-230.
20. Kordower J, Freeman T, Chen E, et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 1998;13:383-393.
21. Brundin P, Isacson O, Gage F, Bjorklund A. Intrastriatal grafting of dopamine-containing neuronal cell suspensions: effects of mixing with target or non-target cells. Dev Brain Res 1986;24:77-84.
22. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA 1990;87:4078-4082.
23. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 1990;526:303-307.
24. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann Neurol 1992;32:543-550.
25. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
26. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999;56:179-187.
27. Lindvall O, Rehncrona S, Gustavi B, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet 1988;2:1483-1484.
28. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia 1964;20:398-399.
29. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic. II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci 1987;7:3915-3934.
30. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999;122:1421-1436.
31. Costantini LC, Lin L, Isacson O. Medial fetal ventral mesencephalon: a preferred source for dopamine neuron grafts. Neuroreport 1997;8:2253-2257.
32. German DC, Manaye KF, Sonsalla PK, Brooks BA. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann N Y Acad Sci 1992;648:42-62.
33. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000;48:689-695.
34. Mendez I, Dagher A, Hong M. Simultaneous intraputaminal and intranigral fetal dopaminergic grafts in Parkinson's disease: first clinical trials. Exp Neurol 2000;164:464.
35. Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998;1:290-295.
36. Lee SH, Lumelsky N, Studer L, et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000;18:675-679.
37. Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000;28:31-40.
38. Wagner J, Akerud P, Castro DS, et al. Induction of a midbrain dopaminergic phenotype in Nurrl-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 1999;17:653-659.
39. Deacon T, Dinsmore J, Costantini L, et al. Blastula-stage stem cells differentiate into dopaminergic and serotonergic neurons after transplantation. Exp Neurol 1998;149:28-41.
40. Brundin P, Bjorklund A. Survival of expanded dopaminergic precursors is critical for clinical trials. Nat Neurosci 1998;1:537.
41. Mahalik T, Finger T, Stromberg I, Olson L. Substantia nigra transplants into denervated striatum of the rat: ultrastructure of graft and host interconnections. J Comp Neurol 1985;240:60-70.
42. Doucet G, Murata Y, Brundin P, et al. Host afferents into intrastriatal transplants of fetal ventral mesencephalon. Exp Neurol 1989;106:1-19.
43. Bjorklund A. Better cells for brain repair. Nature 1993;362:414-415.
44. Venna N, Sabin T, Ordia J, Mark V. Treatment of severe Parkinson's disease by intraventricular injection of dopamine. Appl Neurophysiol 1984;47:62-64.
45. Gerfen C, Keefe K, Steiner H. Dopamine-mediated gene regulation in the striatum. Adv Pharmacol 1998;42:670-673.
46. Onn S-P, West AR, Grace AA. Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000;23:S45-S56.
47. Nutt JG, Obeso JA, Stocchi F. Continuous dopamine-receptor stimulation in advanced Parkinson's disease. Trends Neurosci 2000;23:S109-S115.
48. Strecker RE, Jacobs BL. Substantia nigra dopaminergic unit activity in behaving cats: effects of arousal on spontaneous discharge and sensory evoked activity. Brain Res 1985;361:339-350.
49. Ljungberg T, Apicella P, Schultz W. Responses of monkey dopamine neurons during learning of behavioral reactions. J Neurophysiol 1992;67:145-163.
50. Freeman AS, Meltzer LT, Bunney BS. Firing properties of substantia nigra dopaminergic neurons in freely moving rats. Life Sci 1985;36:1983-1994.
51. Johnson SW, Seutin V, North RA. Burst firing in dopamine neurons induced by N-methyl-D-aspartate: role of electrogenic sodium pump. Science 1992;258:665-667.
52. Grace AA. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
53. Zetterstrom T, Brundin P, Gage FH, et al. In vivo measurement of spontaneous release and metabolism of dopamine from intrastriatal nigral grafts using intracerebral dialysis. Brain Res 1986;362:344-349.
54. Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000;123:1365-1379.
55. Nakao N, Ogura M, Nakai K, Itakura T. Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease. J Neurosci 1998;18:1806-1817.
56. Collier T, Redmond DJ, Roth R, et al. Metabolic energy capacity of dopaminergic grafts and the implanted striatum in parkinsonian nonhuman primates as visualized with cytochrome oxidase histochemistry. Cell Transplant 1997;6:135-140.
57. Brownell AL, Livni E, Galpern W, Isacson O. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 1998;43:387-390.
58. Strecker R, Sharp T, Brundin P, et al. Autoregulation of dopamine release and metabolism by intrastriatal nigral grafts as revealed by intracerebral dialysis. Neuroscience 1987;22:169-178.
59. Galpern WR, Burns LH, Deacon TW, et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996;140:1-13.
60. Gaudin D, Rioux L, Bedard P. Fetal dopamine neuron transplants prevent behavioral supersensitivity induced by repeated administration of L-dopa in the rat. Brain Res 1990;506:166-168.
61. Schultzberg M, Dunnett SB, Bjorklund A, et al. Dopamine and cholecystokinin immunoreactive neurones in mesencephalic grafts reinnervating the neostriatum: evidence for selective growth regulation. Neuroscience 1984;12:17-32.
62. Nilsson OG, Clarke DJ, Brundin P, Bjorklund A. Comparison of growth and reinnervation properties of cholinergic neurons from different brain regions grafted to the hippocampus. J Comp Neurol 1988;268:204-222.
63. Haber SN, Ryoo H, Cox C, Lu W. Subsets of midbrain dopaminergic neurons in monkeys are distinguished by different levels of mRNA for the dopamine transporter: comparison with the mRNA for the D2 receptor, tyrosine hydroxylase and calbindin immunoreactivity. J Comp Neurol 1995;362:400-410.
64. Blanchard V, Raisman-Vozari R, Vyas S, et al. Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res 1994;22:29-38.
65. McCaffery P, Drager UC. High levels of a retinoic acid-generating dehydrogenase in the meso-telencephalic dopamine system. Proc Natl Acad Sci USA 1994;91:7772-7776.
66. Mayer E, Fawcett JW, Dunnett SB. Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons. II. Effects on nigral transplants in vivo. Neuroscience 1993;56:389-398.
67. Mott JL, Eken S, Bowenkamp K, et al. Effects of glial cell line-derived neurotrophic factor on dopaminergic transplants to the 6-OHDA denervated striatum. Abstr Soc Neurosci 1996;22:1492.
68. Meyer M, Zimmer J, Seiler RW, Widmer HR. GDNF increases the density of cells containing calbindin but not of cells containing calretinin in cultured rat and human fetal nigral tissue. Cell Transplant 1999;8:25-36.
69. Janec E, Burke RE. Naturally occurring cell death during postnatal development of the substantia nigra pars compacta of rat. Mol Cell Neurosci 1993;4:30-35.
70. Bjorklund A, Schmidt RH, Stenevi U. Functional reinnervation of the neostriatum in the adult rat by use of intraparenchymal grafting of dissociated cell suspensions from the substantia nigra. Cell Tissue Res 1980;212:39-45.
71. Dunnett SB, Bunch ST, Gage FH, Bjorklund A. Dopamine-rich transplants in rats with 6-OHDA lesions of the ventral tegmental area. 1. Effects on spontaneous and drug-induced locomotor activity. Behav Brain Res 1984;13:71-82.
72. Abrous N, Guy J, Vigny A, et al. Development of intracerebral dopaminergic grafts: a combined immunohistochemical and autoradiographic study of its time course and environmental influences. J Comp Neurol 1988;273:26-41.
73. Clarke DJ, Brundin P, Strecker RE, et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: ultrastructural evidence for synapse formation using tyrosine hydroxylase immunocytochemistry. Exp Brain Res 1988;73:115-126.
74. Leigh K, Elisevich K, Rogers KA. Vascularization and microvascular permeability in solid versus cell-suspension embryonic neural grafts. J Neurosurg 1994;81:272-283.
75. Nikkah G, Cunningham MG, Jodicke A, et al. Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res 1994;633:133-143.
76. Hernit-Grant CS, Macklis JD. Embryonic neurons transplanted to regions of targeted photolytic cell death in adult mouse somatosensory cortex re-form specific callosal projections. Exp Neurol 1996;139:131-142.
77. Sotelo C, Alvarado-Mallart RM. Embryonic and adult neurons interact to allow Purkinje cell replacement in mutant cerebellum. Nature 1987;327:421-423.
78. Costantini LC, Snyder-Keller A. Co-transplantation of fetal lateral ganglionic eminence and ventral mesencephalon can augment function and development of intrastriatal transplants. Exp Neurol 1997;145:214-227.
79. Galpern WR, Burns LH, Deacon TW, et al. Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996;140:1-13.
80. Graybiel AM, Hirsch E, Agid Y. The nigrostriatal system in Parkinson's disease. In: Streifler MB, Korczyn AD, Melamed E, Youdim MBH, eds. Advances in neurology. New York: Raven Press, 1990:17-29.
81. Johansson M, Friedemann M, Hoffer B, Stromberg I. Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp Neurol 1995;134:25-34.
82. Sanghera MK, Manaye K, McMahon A, et al. Dopamine transporter mRNA levels are high in midbrain neurons vulnerable to MPTP. Neuroreport 1997;8:3327-3331.
83. Ciliax BJ, Drash GW, Staley JK, et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 1999;409:38-56.
84. Falkenburger BH, Barstow KL, Mintz IM. Dendrodendritic inhibition through reversal of dopamine transport. Science 2001;293:2465-2470.
85. Hantraye P, Riche D, Maziere M, Isacson O. Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc Natl Acad Sci USA 1992;89:4187-4191.
86. Hantraye P, Riche D, Maziere M, Isacson O. A primate model of Huntington's disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 1990;108:91-104.
87. Burns LH, Pakzaban P, Deacon TW, et al. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 1995;64:1007-1017.
88. Hemmati-Brivanlou A, Melton D. Vertebrate embryonic cells will become nerve cells unless told otherwise. Cell 1997;88:13-17.
89. Mandel R, Rendahl K, Spratt S, et al. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998;18:4271-4284.
90. Marsden CD. Basal ganglia disease. Lancet 1982:1141-1147.
91. Montgomery R, Warner M, Lum B, Spear P. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996;87:427-436.
92. Rakic P. Adult neurogenesis in mammals: an identity crisis. J Neurosci 2002;22:614-618.
93. Alvarez-Buylla A, Garcia-Verdugo JM. Neurogenesis in adult subventricular zone. J Neurosci 2002;22:629-634.
94. Flax JD, Aurora S, Yang C, et al. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998;16:1033-1039.
95. Benraiss A, Lerner K, Chmielnicki E, et al. Adenoviral transduction of the ventricular wall with a BDNF expression vector induces neuronal recruitment from endogenous progenitor cells in the adult forebrain. Mol Ther 2000;1:S35-S36.
96. Lim DA, Tramontin AD, Trevejo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron 2000;28:713-726.
97. Shimazaki T, Shingo T, Weiss S. The ciliary neurotrophic factor/leukemia inhibitory factor/gc130 receptor complex operates in the maintenance of mammalian forebrain neural stem cells. J Neurosci 2001;21:7642-7653.
98. Craig CG, Tropepe V, Morshead CM, et al. In vivo growth factor expansion of endogenous subependymal neural precursor cell population in the adult mouse brain. J Neurosci 1996;16:2649-2658.
99. Fallon J, Reid S, Kinyamu R, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci USA 2000;97:14686-14691.
100. Zurn AD, Widmer HR, Aebischer P. Sustained delivery of GDNF: towards a treatment for Parkinson's disease. Brain Res 2001;36:222-229.
101. Lebel M, Gauthier Y, Moreau A, Drouin J. Pitz3 activates mouse tyrosine hydroxylase promoter via a high-affinity binding site. J Neurochem 2001;77:558-567.
102. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurrl is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA 1998;95:4013-4018.
103. Wallen AA, Castro DS, Zetterstrom RH, et al. Orphan nuclear receptor Nurrl is essential for Ret expression in midbrain dopamine neurons and in the brain stem. Mol Cell Neurosci 2001;18:649-663.
104. Tornqvist N, Hermanson E, Perlmann T, Stromberg I. Generation of tyrosine hydroxylase-immunoreactive neurons in ventral mesencephalic tissue of Nurrl deficient mice. Brain Res Dev Brain Res 2002;133:37-47.
105. Akerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001;21:8108-8118.
106. Eberhardt O, Coelin RV, Kugler S, et al. Protection by synergistic effects of adenovirus-mediated X-linked chromosome-linked inhibitor of apoptosis and glial-derived neurotrophic factor gene transfer in the 1-methyl-4-pheyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 2002;20:9126-9134.
107. Schumacher JM, Short MP, Hyman BT, et al. Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience 1991;45:561-570.
108. Frim DM, Uhler TA, Galpern WR, et al. Biologically delivered BDNF increases dopaminergic neuronal survival in a rat model of Parkinson's disease. Proc Natl Acad Sci USA 1994;91:5104-5108.
109. Mufson EJ, Kroin JS, Sobreviela T, et al. Intrastriatal infusions of brain-derived neurotrophic factor: retrograde transport and colocalization with dopamine containing substantia nigra neurons in rat. Exp Neurol 1994;129:15-26.
110. Check E. Parkinson's patients show positive response to implants. Nature 2002;416:666.